Role of the hepatitis Delta virus on the pathogenesis of hepatic cirrhosis and hepatocellular carcinoma. Recent advances;Ruolo del virus dell'epatite delta nella patogenesi della cirrosi epatica e del carcinoma epatocellulare: Attuali acquisizioni

Recenti Progressi in Medicina

Volumn 101, Issue 2, 2010, Pages 52-56

  Romeo, Raffaella ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hepatic cirrhosis; Hepatitis B virus; Hepatitis delta virus; Hepatocellular carcinoma; Inteferon

Indexed keywords

ADEFOVIR; CD4 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; RIBAVIRIN;

BLOOD; BODY FLUID; DELTA AGENT HEPATITIS; ERADICATION THERAPY; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; PATHOGENESIS; PREVALENCE; PROGNOSIS; REVIEW; RNA VIRUS; SUPERINFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DEFECTIVE VIRUSES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PREVALENCE; RNA, VIRAL; VIRUS REPLICATION;

EID: 77951834492     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: 10.1701/478.5631     Document Type: Review

References (41)

1. Sureau C, Guerra B, Lanford R. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis Delta virion. J Virol 1993; 67: 366-372 (Pubitemid 23002999)
2. Rizzetto M, Hoyer B, Canese MG, et al. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA 1980; 77: 6124-6128 (Pubitemid 11206354)
3. Shakil AO, Hadziyannis S, Hoofnagle JH, et al. Geographic distribution and genetic variability of hepatitis delta virus genotype I. Virology 1997; 234:160-167 (Pubitemid 27316617)
4. Sakugawa H, Nakasone H, Nakayoshi T, et al. Hepatitis Delta virus genotype lib predominates in an endemic area, Okinawa, Japan. J Med Virol 1999; 58: 366-372 (Pubitemid 29326050)
5. Watanabe H, Nagayama K, Enomoto M, et al. Chronic hepatitis delta virus infection with genotype lib variants correlated with progressive liver disease. J Gen Virol 2003; 84: 3275-3289 (Pubitemid 37540756)
6. Casey JL, Niro GA, Engle R, et al. Hepatitis B virus/hepatitis D virus co-infection in outbreaks of cute hepatitis in the Peruvian Amazon basin: the role of HDV genotype III and HBV genotype F. J Infect Dis 1996; 174: 920-926 (Pubitemid 26357452)
7. Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a delta virus genus of at least seven major clades. J Virol 2004; 78: 2537-2544 (Pubitemid 38228948)
8. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 (S1): S212-9.
9. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine 1990; 8: S10-4. (Pubitemid 20154748)
10. Rizzetto M, Hadziyannis SJ, Hansson BG, et al. Hepatitis delta virus infection in the world: epidemiological patterns and clinical expression. Gastroenterol Int 1992; 5: 18-32.
11. Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117: 161-166 (Pubitemid 29297633)
12. Sagnelli E, Stroffolini T, Ascione A, et al. Decrease in HDV endemicity in Italy. J Hepatol 1997; 26: 20-24
13. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000; 32: 824-827
14. Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis 2007; 44: 17-24.
15. Cross TJS, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in south London. J Med Virol 2008; 80: 277-282
16. Wedemeyer H, Heidrich B, Manns M. Hepatitis D virus infection. Not a vanishing disease in Europe! Hepatology 2007; 45: 1331-1332
17. Le Gal F, Castelneau C, Gault E, et al. Hepatitis D virus infection. Not a vanishing disease in Europe! Reply Hepatology 2007; 45: 1332-1333
18. Negro F, Rizzetto M. Diagnosis of hepatitis Delta virus infection. J Hepatol 1995; 22: S136-9.
19. Rizzetto M, Verme G, Recchia S, et al. Chronic HBsAg hepatitis with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98: 437-441
20. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46: 420-426 (Pubitemid 30313398)
21. McFarlane BM, Bridger CB, Smith HM, et al. Autoimmune mechanisms in chronic hepatitis B and delta virus infections. Eur J Gastroenterol Hepatol 1995; 57:615-621
22. Nisini R, Paroli M, Accapezzato D, et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997; 71: 2241-2251 (Pubitemid 27078605)
23. Lefkowich JH, Goldstein H, Yatto R, et al. Cytopathic liver injury in acute delta virus hepatitis. Gastroenterology 1987; 92: 1262-1266 (Pubitemid 17055917)
24. Nakano T, Shapiro CN, Hadler SC, et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol 2001; 82: 2183-2189 (Pubitemid 32827598)
25. Lee CM, Chanchien CS, Chung JC, et al. Characterization of a new genotype II hepatitis delta virus from Taiwan. J Med Virol 1996; 49:145-154
26. Niro GA, Smedile A, Andriulli A, et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25: 728-734 (Pubitemid 27106461)
27. Caredda F, d'Arminio Monforte A, Rossi E, et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res 1983; 143: 245-250
28. Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108: 796-802.
29. Romeo R, Del Ninno E, Rumi MG, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136:1629-1638
30. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.
31. Farci P, Mandras A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94.
32. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749 (Pubitemid 38736339)
33. Ferenci P, Formann E, Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol 2005; 100: 1626-1627 (Pubitemid 41032380)
34. Castelneau C, Le Gal FL, Ripault M, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-735 (Pubitemid 44433730)
35. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-720 (Pubitemid 44433728)
36. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. J Viral Hepat 2008; 15:314-321 (Pubitemid 351326903)
37. Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferon alfa treatment of children with chronic hepatitis delta: a multi center study. J Viral Hepat 1996; 3: 123-128 (Pubitemid 126734178)
38. Casey J, Cote PJ, Toshkov IA, et al. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother 2005; 49: 4396-4399 (Pubitemid 41400998)
39. Bordier BB, Marion PL, Ohashi K, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002; 76:10465-10472
40. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112: 407-414
41. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-3652